News Quantified

SOMMY – sumitomo chem unsp/adr (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Poxel Reports Revenue for the First Quarter 2024 and Provides Corporate Update [Yahoo! Finance]

Sumitomo Pharma Presents Urology and Oncology Data at AUA 2024 Annual Meeting [Yahoo! Finance]

Poxel Provides a Financial Update for the First Quarter 2024 and Announces the Postponement of its 2023 Full-Year Results Release [Yahoo! Finance]

China Veterinary Medicine Market Analysis Report 2024-2030, Featuring China Animal Husbandry Industry, Boehringer Ingelheim, Bimeda, Merck, CEVA, Zoetis Services, Virbac and Vetoquinol [Yahoo! Finance]

Roivant announces $1.5B share buyback, positive Phase 2 data Apr. 02, 2024 9:20 AM ET By: Val Brickates Kennedy , SA News Editor [Seeking Alpha]

Top News Gainers

3/2 Boston Biomedical, Inc. Announces Investment by its Parent Company in MPM Oncology Innovations Fund 3.8%

10/11 Nihon Medi-Physics Launches In-house Production of Molybdenum-99 3.0%

11/22 Form F-6EF Sumitomo Chemical Co., Filed by: JPMorgan Chase Bank, N.A. - ADR Depositary 2.3%

5/14 Tolero Pharmaceuticals Announces First Patient Dosed in Phase 1 Study of Investigational Agent TP-3654 in Patients with Advanced Solid Tumors 2.3%

4/6 Boston Biomedical, Inc. Announces First Patient Dosed in Phase 1 Study of Investigational Agent TP-3654 in Patients with Myelofibrosis 1.9%

12/12 Sunovion Announces Results from Its Open-Label Extension Study of SEP-363856 in Schizophrenia 1.5%

5/10 Sunovion and PsychoGenics Announce that SEP-363856 Has Received FDA Breakthrough Therapy Designation for the Treatment of People with Schizophrenia 1.1%

8/8 SUMITOMO CHEM C/ADR (OTCMKTS: SOMMY) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 1.0%

7/30 Sunovion Announces Acceptance by the U.S. FDA of the New Drug Application for Dasotraline for the Treatment of Adults with Moderate-to-Severe Binge Eating Disorder 0.8%

6/6 Boston Biomedical, Inc. Announces the Continuation of the Phase 3 CanStem303C Study of Napabucasin in Patients with Advanced Colorectal Cancer Following Interim Analysis 0.7%

Top News Decliners

3/26 Tolero Pharmaceuticals Joins The Leukemia & Lymphoma Society's Groundbreaking Beat AML Master Clinical Trial for Patients with Acute Myeloid Leukemia -7.3%

9/27 Sunovion and PsychoGenics Initiate DIAMOND Phase 3 Clinical Studies for SEP-363856 in the Treatment of Adults and Adolescents with Schizophrenia -4.3%

3/6 SUMITOMO CHEM C/ADR (OTCMKTS: SOMMY) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -3.7%

4/12 Inspired By Nature, Zymergen Brews High-Performance Bio-Electronics [Forbes] -2.2%

5/30 Tolero Pharmaceuticals Advances Investigational Agent TP-0903 into Phase 1b Expansion Stage of Study in Patients with Advanced Solid Tumors -1.8%

7/31 Nufarm Announces Placement Of $97.5 Mln Preference Securities To Sumitomo Chemical Co [Reuters] -1.5%

8/14 Sunovion Receives 2018 Corporate Responsibility and Leadership Awards from United Way of Tri-County and Expands Partnership For 8th Annual Community Service Program -1.5%

2/11 For The First Time Ever, A Drug Developed By AI Will Be Tested In Human Trials [Forbes] -1.3%

9/28 Tolero Pharmaceuticals Presents Preliminary Findings from Phase 1 Study Evaluating Investigational Agent TP-0903 in Patients with Advanced Solid Tumors at ESMO 2019 -1.3%

6/12 Tolero Pharmaceuticals Announces First Patient Dosed with Investigational Agent TP-0903 in Phase 1/2 Study in Patients with Previously Treated Chronic Lymphocytic Leukemia andSmall Lymphocytic Lymphoma -1.0%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day